Next Phase Newsletter

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Partnering launches for Digital RESI JPM next week and we are expecting 400-500 investors, including family offices/private wealth, corporate venture capital, large pharma and strategic groups, and more. A diverse assembly of investors participate at every RESI event with a main objective of sourcing early-stage innovations for potential investment, in-licensing, and other partnering strategies. Check out the investors who are currently confirmed to attend:

Confirmed Digital RESI JPM Investors*

Don’t miss the last opportunity to save on registration! Early bird rates end tomorrow, so sign up now to save $200! if you are actively fundraising and seeking to engage with investors that could potentially be interested in your technology, do not miss out on this opportunity and secure the best registration price available!

By Karen Deyo, Director of Investor Research, Israel BD, LSN

Through the years, we at Life Science Nation (LSN) have spoken to startups, investors, service providers and many of the other players in the early-stage life science ecosystem. We have seen what works and what does not, and have put together a series of workshops and bootcamps to pass along this knowledge to emerging startups, to help smooth their journeys and, hopefully, prevent them from making a few common mistakes along the way.

Over the course of the next few weeks, leading up to Digital RESI JPM, January 11-13, LSN staff will be holding a series of free bootcamps for startups. Fundraising executives are welcome to attend as many as they desire! We will cover topics such as (but not limited to): identifying investors who are a fit for you, building a comprehensive marketing collateral package that tells your story, how to optimize your partnering experience at a conference, and how to approach your investor meetings in a way that will increase your chances of a second meeting. Follow the links below to register!

Don’t forget to register for Digital RESI JPM – partnering launches next Monday, December 20, so make sure you are signed up to start booking meetings!

By Candice He, Vice President of Business Development, Global Investment Strategist, LSN

Life science startups face a myriad of unique challenges due to the complexity of the healthcare system, including potentially years-long paths to market, regulatory hurdles, and possible reimbursement issues. All of these areas, among others, present opportunities for service providers to lend their expertise, preventing startups from costly mistakes that could prevent their products from reaching the market due to reasons other than a failure in the technology.

While connecting startups with investors is a large part of our work, Life Science Nation has also emphasized the importance of the presence of service providers at our Redefining Early Stage Investment (RESI) conferences.  RESI’s unique partnering platform allows attendees to filter the companies by sector, indication, and stage of development, among other criteria, so your target leads will be just a few clicks away.

While RESI partnering provides a powerful avenue to identify new clients, service providers that attend RESI have the option of multiple levels of participation, improving their exposure beyond that generated by partnering outreach. This can include:

Hosting a 1-hour live workshop to introduce your service

• Open to all registered RESI attendees
• The recording will be posted on the sponsor dedicated webpage (a virtual exhibition table) at RESI live agenda for a month, during which you can expect some attendees to contact you in partnering (Check Out an Example Here: McDermott Will & Emery)
• After the conference, a detailed report on the workshop audience will be provided

Get a spotlight on Life Science Nation’s Weekly Newsletter, with a readership of 50,000+

• Newsletter Interview: Tell our readers more about your services/products or provide sights on a related topic in the format of podcase or article (Learn more about a recent workshop in a newsletter article)
• Newsletter Banner Ad: feature your brand logo and website

Interested in learning more about the opportunities available at RESI? Make sure to check out the full sponsorship brochure below!

By Rory McCann, Marketing Manager & Conference Producer, LSN

It seems like not much time has passed since events around the world opened back up for in-person attendance. However, with the emergence and spread of the Omicron variant of COVID-19, many who had enthusiastically jumped back into in-person networking are asking, “What now?”

Whether discussing COVID-19 or fundraising in general, there is no crystal ball, leaving many to wander around in the dark hoping to make the most of uncertain times. In the absence of future forecasting, what I can offer instead are principles of partnering that are consistent and productive, no matter the state of the world around you.

Partnering is a numbers game, but not one of luck. Success takes research, strategy, patience, follow-up, and the ability to take feedback constructively. To prove that these aren’t new principles, check out these past interviews and articles outlining what successful partnering looks like. The truth is that there is no perfect environment for fundraising. Whether the Omicron variant throwing a wrench into the best-laid plans of in-person meetings or another event that gets in the way, solid principles will carry into successful partnering and lead to powerful partnerships in the future.

• Embracing the Early-Stage Journey
• Does RESI Work?
• Telling Your Story
• Getting it Right from Pitch to Partner
• Getting Ready for Successful Partnering Meetings
• Nailing the Digital Handshake for Online Investor Meetings
• How to Fail
• The Lost Art of Following Up
• What Successful Partnering Really Looks Like

Learn more about how Life Science Nation can help you with your fundraising efforts and check out the newest digital  Redefining Early Stage Investment (RESI) conference, January 11-13. Early bird rates apply until December 17!

A healthcare investment firm based in the USA with multiple billion dollars in assets under management. The firm invests in life science companies and is currently investing out of its fifth fund. The firm looks to invest in companies globally, with a focus on companies located in the United States.

The firm is interested in therapeutics, medical devices and diagnostics, although the majority of the firm’s investments have been in the therapeutics space. The firm is primarily interested in Series A, B, and C opportunities, with a focus on therapeutics that have strong preclinical data or are peri-clinical. The firm also has special interests in oncology, infectious diseases, rare diseases, dermatology and autoimmune disorders.

The firm is looking for companies with significant competitive advantage and strong, experienced management teams. The firm is willing to invest in both publicly and privately held companies. The firm is open to both lead and co-investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The firm is a venture fund based in San Diego, California, founded in 2021. The firm has $750 AUM for their first fund and will invest from early to later stage companies. The firm is interested in therapeutics, companion diagnostics, precision medicine, tools and manufacturing services. The firm generally invests $10M or more, but may participate in earlier rounds, primarily as a fund of funds. The firm will invest globally, and prefers companies developing platform technologies or with multiple assets.

Within therapeutics, the firm is interested in small molecules, biologics and cell and gene therapies. Outside of therapeutics, the firm is interested in companion diagnostics, precision medicine, life science tools, and novel manufacturing technologies. Indications of interest include oncology/IO, neurodegeneration, autoimmune disorders, cardiometabolic disorders and rare diseases. The firm is willing to invest from pre-IND all the way to PIPEs.

The firm is willing to lead or co-invest, but is a very active investor, and will take at least one board seat after investment. As an individual investor, the firm prefers to invest at least $10M per company, but may invest in smaller rounds as an LP of another investment firm.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.